摘要
目的探讨不同浓度三氧化二砷（As2O3，ATO）对BXSB狼疮小鼠肾组织中神经激肽A（NKA）含量的影响及其意义。方法BXSB狼疮小鼠50只随机分为5组，分别为对照组，系统性红斑狼疮（SLE）组，低剂量、中剂量和高剂量ATO组。常规检验治疗前后小鼠的血生化指标、组织化学法观察肾脏病理改变、酶联免疫吸附试验（ELISA）及反转录-聚合酶链反应（RT—PCR）法检测各组NKA及肾组织中NKAmRNA含量。结果BXSB狼疮小鼠肾组织中NKA的含量（299±26）pg／g高于健康对照组（122±7）p以，差异有统计学意义（P〈0．05）。ATO作用BXSB狼疮小鼠后，其肾组织的NKA含量明显下降，大、中、小剂量组与治疗前的差异均具有统计学意义（P〈0．05）。同时，各项生化指标及肾脏病理改变也明显改善（P〈0．05），尤其以小剂量ATO组效果更好（P〈0．01）；小剂量ATO组中毒症状较轻，中、大剂量组中毒症状较重，两者差异有统计学意义（P〈0．05）。结论一定剂量的ATO对狼疮肾具有治疗作用，其机制可能是下调肾组织中NKA mRNA表达，其中小剂量ATO治疗狼疮肾，既安全又有效，具有一定的应用前景。
Objective To investigate the effect of different concentrations of arsenic trioxide （As2O3, ATO） on neurokinin A （NKA） in renal tissue of BXSB mice and explore its clinical value. Methods Fifty BXSB mice （twelve weeks old and weighted 23 -26 g） were randomly divided into control group, systemic lupus erythematosus （SLE） group, and therapeutic group of three different concentrations of ATO. All biochemical indicators were analyzed before and after treatment. The pathology of renal tissue was examined by immunohistochemistry. The concentration of NKA in renal tissues was detected by ELISA and the concentration of NKA mRNA was detected by RT-PCR. Results The concentration of NKA in SLE group in renal tissue （299±26） pg/g was significantly higher than that of normal control group （122±7） pg/g （P〈0.05）. The concentration of NKA in the SLE group in renal tissue was significantly higher than that of three different concentrations of ATO in low-dose group （151±14） pg/g, moderate-dose group （147±9） pg/g and in high- dose group （155±14） pg/g （P〈0.05）. No difference was found between three different dosages of ATO treatment groups and normal control groups （P〉0.05）. There were no significant differences among three different dosages of ATO treatment group （P〉0.05）. The side effects in low-dose group were significantly lower than those of moderate and high-dosage groups （P〈0.05）. Conclusion NKA concentration expressed in the renal tissues in the SLE group is higher than that in the control group. Decreasing the concentrations of NKA mRNA in renal tissues may be one of the important mechanisms of ATO in treating SLE. Low-dosage ATO is safe and effective to treat SLE and has therapeutic potentials.
出处
《中华风湿病学杂志》
CAS
CSCD
北大核心
2009年第5期309-312,共4页
Chinese Journal of Rheumatology
关键词
红斑狼疮
系统性
神经激肽A
狼疮肾炎
三氧化二砷
Lupus erythematosus, systemic
Neurokinin A
Lupus nephritis
Arsenic trioxide
